The effect of TIcagrelor administered through a nasogastric tube to COMAtose patients undergoing acute percutaneous coronary intervention: The TICOMA study

EuroIntervention

Volumn 12, Issue 14, 2017, Pages 1782-1788

  Ratcovich, Hanna ^a   Sadjadieh, Golnaz ^a   Andersson, Hedvig B ^a,b   Frydland, Martin ^a   Wiberg, Sebastian ^a   Dridi, Nadia P ^a   Kjaergaard, Jesper ^a   Holmvang, Lene ^a  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

High platelet reactivity; OHCA; Platelet function; Primary PCI; Ticagrelor; VerifyNow

Indexed keywords

AR C 124910XX; DRUG METABOLITE; TICAGRELOR; UNCLASSIFIED DRUG; ADENOSINE; ANTITHROMBOCYTIC AGENT; AR C124910XX; PURINERGIC P2Y RECEPTOR ANTAGONIST;

ADULT; AGED; ARTICLE; COMATOSE PATIENT; CONTROLLED STUDY; DENMARK; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NASOGASTRIC TUBE; OBSERVATIONAL STUDY; OUT OF HOSPITAL CARDIAC ARREST; PERCUTANEOUS CORONARY INTERVENTION; PHARMACODYNAMICS; PHARMACOKINETICS; PLATELET REACTIVITY; PROSPECTIVE STUDY; RESUSCITATION; TABLET FORMULATION; ANALOGS AND DERIVATIVES; BLOOD CLOTTING PARAMETERS; DRUG EFFECTS; MIDDLE AGED; MYOCARDIAL INFARCTION; PROCEDURES; THROMBOCYTE;

ADENOSINE; BLOOD PLATELETS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PURINERGIC P2Y RECEPTOR ANTAGONISTS;

EID: 85016029224     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJ-D-16-00398     Document Type: Article

References (25)

1. Noc M, Fajadet J, Lassen JF, Kala P, MacCarthy P, Olivecrona GK, Windecker S, Spaulding C; European Association for Percutaneous Cardiovascular Interventions (EAPCI); Stent for Life (SFL) Group. Invasive coronary treatment strategies for outof-hospital cardiac arrest: a consensus statement from the European association for percutaneous cardiovascular interventions (EAPCI)/stent for life (SFL) groups. EuroIntervention. 2014;10:31-7.
2. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, van 't Hof A, Widimsky P, Zahger D. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33:2569-619.
3. Steblovnik K, Blinc A, Bozic-Mijovski M, Kranjec I, Melkic E, Noc M. Platelet reactivity in comatose survivors of cardiac arrest undergoing percutaneous coronary intervention and hypothermia. EuroIntervention. 2015;10:1418-24.
4. Cornish P. Avoid the crush: hazards of medication administration in patients with dysphagia or a feeding tube. CMAJ. 2005; 172:871-2.
5. Boucher BA, Wood GC, Swanson JM. Pharmacokinetic changes in critical illness. Crit Care Clin. 2006;22:255-71, v.i.
6. Gouffran G, Rosencher J, Bougouin W, Jakamy R, Joffre J, Lamhaut L, Dumas F, Cariou A, Varenne O. Stent thrombosis after primary percutaneous coronary intervention in comatose survivors of out-of-hospital cardiac arrest: Are the new P2Y12 inhibitors really more effective than clopidogrel? Resuscitation. 2016;98:73-8.
7. Joffre J, Varenne O, Bougouin W, Rosencher J, Mira JP, Cariou A. Stent thrombosis: an increased adverse event after angioplasty following resuscitated cardiac arrest. Resuscitation. 2014;85:769-73.
8. Bednar F, Kroupa J, Ondrakova M, Osmancik P, Kopa M, Motovska Z. Antiplatelet efficacy of P2Y12 inhibitors (prasugrel, ticagrelor, clopidogrel) in patients treated with mild therapeutic hypothermia after cardiac arrest due to acute myocardial infarction. J Thromb Thrombolysis. 2016;41:549-55.
9. Parodi G, Xanthopoulou I, Bellandi B, Gkizas V, Valenti R, Karanikas S, Migliorini A, Angelidis C, Abbate R, Patsilinakos S, Baldereschi GJ, Marcucci R, Gensini GF, Antoniucci D, Alexopoulos D. Ticagrelor crushed tablets administration in STEMI patients: the MOJITO study. J Am Coll Cardiol. 2015;65:511-2.
10. Teng R, Carlson G, Hsia J. An open-label, randomized bioavailability study with alternative methods of administration of crushed ticagrelor tablets in healthy volunteers. Int J Clin Pharmacol Ther. 2015;53:182-9.
11. Aradi D, Storey RF, Komocsi A, Trenk D, Gulba D, Kiss RG, Husted S, Bonello L, Sibbing D, Collet JP, Huber K; Working Group on Thrombosis of the European Society of Cardiology. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J. 2014;35:209-15.
12. Nielsen N, Wetterslev J, Cronberg T, Erlinge D, Gasche Y, Hassager C, Horn J, Hovdenes J, Kjaergaard J, Kuiper M, Pellis T, Stammet P, Wanscher M, Wise MP, Åneman A, Al-Subaie N, Boesgaard S, Bro-Jeppesen J, Brunetti I, Bugge JF, Hingston CD, Juffermans NP, Koopmans M, Køber L, Langørgen J, Lilja G, Møller JE, Rundgren M, Rylander C, Smid O, Werer C, Winkel P, Friberg H; TTM Trial Investigators. Targeted temperature management at 33 degrees C versus 36 degrees C after cardiac arrest. N Engl J Med. 2013;369:2197-206.
13. Husted SE, Storey RF, Bliden K, Tantry US, Høimark L, Butler K, Wei C, Teng R, Gurbel PA. Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. Clin Pharmacokinet. 2012;51:397-409.
14. Moudgil R, Al-Turbak H, Osborne C, Hibbert B, So DY, Le May MR; CAPITAL Investigators. Superiority of ticagrelor over clopidogrel in patients after cardiac arrest undergoing therapeutic hypothermia. Can J Cardiol. 2014;30:1396-9.
15. Tilemann LM, Stiepak J, Zelniker T, Chorianopoulos E, Giannitsis E, Katus HA, Müller OJ, Preusch M. Efficacy of enteral ticagrelor in hypothermic patients after out-of-hospital cardiac arrest. Clin Res Cardiol. 2016;105:332-40.
16. Alexopoulos D, Barampoutis N, Gkizas V, Vogiatzi C, Tsigkas G, Koutsogiannis N, Davlouros P, Hahalis G, Nylander S, Parodi G, Xanthopoulou I. Crushed Versus Integral Tablets of Ticagrelor in ST-Segment Elevation Myocardial Infarction Patients: A Randomized Pharmacokinetic/Pharmacodynamic Study. Clin Pharmacokinet. 2016;55:359-67.
17. Rollini F, Franchi F, Hu J, Kureti M, Aggarwal N, Durairaj A, Park Y, Seawell M, Cox-Alomar P, Zenni MM, Guzman LA, Suryadevara S, Antoun P, Bass TA, Angiolillo DJ. Crushed Prasugrel Tablets in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention: The CRUSH Study. J Am Coll Cardiol. 2016;67:1994-2004.
18. Hobl EL, Reiter B, Schoergenhofer C, Schwameis M, Derhaschnig U, Kubica J, Stimpfl T, Jilma B. Morphine decreases ticagrelor concentrations but not its antiplatelet effects: a randomized trial in healthy volunteers. Eur J Clin Invest. 2016; 46:7-14.
19. Kubica J, Adamski P, Ostrowska M, Sikora J, Kubica JM, Sroka WD, Stankowska K, Buszko K, Navarese EP, Jilma B, Siller-Matula JM, Marsza MP, Ro D, Koziski M. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. Eur Heart J. 2016;37:245-52.
20. Kander T, Brokopp J, Erlinge D, Lood C, Schott U. Temperature effects on haemostasis in whole blood from ticagrelorand aspirin-treated patients with acute coronary syndrome. Scand J Clin Lab Invest. 2015;75:27-35.
21. Jacob M, Hassager C, Bro-Jeppesen J, Ostrowski SR, Thomsen JH, Wanscher M, Johansson PI, Winther-Jensen M, Kjærgaard J. The effect of targeted temperature management on coagulation parameters and bleeding events after out-of-hospital cardiac arrest of presumed cardiac cause. Resuscitation. 2015;96: 260-7.
22. Schneider DJ, Agarwal Z, Seecheran N, Keating FK, Gogo P. Pharmacodynamic effects during the transition between cangrelor and ticagrelor. JACC Cardiovasc Interv. 2014;7:435-42.
23. Bonello L, Laine M, Camoin-Jau L, Noirot F, Guieu R, Dignat-George F, Paganelli F, Frere C. Onset of optimal P2Y12-ADP receptor blockade after ticagrelor and prasugrel intake in Non-ST elevation acute coronary syndrome. Thromb Haemost. 2015;114:702-7.
24. Parodi G, Valenti R, Bellandi B, Migliorini A, Marcucci R, Comito V, Carrabba N, Santini A, Gensini GF, Abbate R, Antoniucci D. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol. 2013;61:1601-6.
25. Silvain J, Storey RF, Cayla G, Esteve JB, Dillinger JG, Rousseau H, Tsatsaris A, Baradat C, Salhi N, Hamm CW, Lapostolle F, Lassen JF, Collet JP, Ten Berg JM, Van't Hof AW, Montalescot G. P2Y12 receptor inhibition and effect of morphine in patients undergoing primary PCI for ST-segment elevation myocardial infarction. The PRIVATE-ATLANTIC study. Thromb Haemost. 2016;116:369-78.